Autonomy Capital (Jersey) L.P. Genmab A/S Transaction History

Autonomy Capital (Jersey) L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$41.55 - $48.72 $2.41 Million - $2.82 Million	-57,968 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$32.88 - $44.57 $26,632 - $36,101	810 Added 1.42%	57,968 $2.37 Million
Q1 2021 May 17, 2021	SELL	$30.92 - $44.4 $36,980 - $53,102	-1,196 Reduced 2.05%	57,158 $1.88 Million
Q4 2020 Feb 16, 2021	BUY	$33.66 - $40.76 $1.96 Million - $2.38 Million	58,354 New	58,354 $2.37 Million

238

52.6M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.3B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Autonomy Capital (Jersey) L.P., based on Form 13F filings with the SEC.

Stay updated on Autonomy Capital (Jersey) L.P. with notifications on news.